ASX:EMD Emyria (EMD) Stock Price, News & Analysis → This AI made her leave her job (From Prosper Trading Academy) (Ad) Free EMD Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume471,333 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Emyria alerts: Email Address Ad Prosper Trading AcademyThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool About Emyria Stock (ASX:EMD)Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.Read More Ad Prosper Trading AcademyThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool EMD Stock News HeadlinesApril 11, 2024 | finance.yahoo.comUS March deficit shrinks as outlays fall, tax receipts riseApril 10, 2024 | finance.yahoo.comEmyria opens Empax Centre to target care gaps in resistant PTSDJanuary 29, 2024 | finance.yahoo.comEmyria Slides As Insider Purchases Lose Another AU$300kJanuary 14, 2024 | au.investing.comEmyria kicks off year with $2.5 million R&D incentive on the heels of Authorised Prescriber statusJanuary 10, 2024 | proactiveinvestors.com.auSEC gives Bitcoin ETFs the long-awaited green lightJanuary 10, 2024 | proactiveinvestors.com.auEmyria sharpens focus on delivering MDMA treatments for PTSD patientsJanuary 10, 2024 | msn.comClosing Bell: The ASX got slow-boiled like a frog in a pot to close at -0.69pc downJanuary 9, 2024 | msn.comASX Health Stocks: Emyria surges 19pc after granting of ‘Authorised Prescriber’ status by TGANovember 21, 2023 | proactiveinvestors.com.auEmyria welcomes top healthcare leader as chairmanNovember 12, 2023 | proactiveinvestors.com.auEmyria restructures board amid cost efficiency commitmentNovember 9, 2023 | finance.yahoo.comIt's Unlikely That Shareholders Will Increase Emyria Limited's (ASX:EMD) Compensation By Much This YearOctober 30, 2023 | proactiveinvestors.com.auEmyria secures ethics endorsement for MDMA Authorised Prescriber application, clearing way for TGA decisionOctober 26, 2023 | finance.yahoo.comEmyria hails strong growth in clinical billingsOctober 21, 2023 | proactiveinvestors.com.auEmyria given green light to import MDMA for therapeutic trials in AustraliaOctober 5, 2023 | au.investing.comEmyria completes entitlement offer, raises $1.18m ahead of MDMA-assisted therapy trialSeptember 26, 2023 | finance.yahoo.comEmyria set to begin MDMA study after securing local supplySeptember 7, 2023 | finance.yahoo.comEmyria provides unique combination of drug development and therapy deliverySeptember 4, 2023 | msn.comClosing Bell: Liontown’s kitty is sitting pretty; Benchmark makes most of Monday ahead of RBA meetSeptember 4, 2023 | proactiveinvestors.com.auEmyria raises $2 million in placement; launches $3.1 million entitlement offerSeptember 3, 2023 | msn.comTop 10 at 11: Emyria soars on funding news, and loads of tasty stuff unearthed in Canada.September 1, 2023 | finance.yahoo.comEmyria Full Year 2023 Earnings: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)August 1, 2023 | finance.yahoo.comEmyria advances development and commercialisation of unique drug productsJuly 11, 2023 | proactiveinvestors.com.auEmyria recruits first patient for MDMA-assisted therapy trialJuly 3, 2023 | proactiveinvestors.com.auEmyria expands mental health care capabilities with Pax Centre acquisitionJune 8, 2023 | proactiveinvestors.com.auEmyria hails ethics approval for MDMA-assisted clinical trialSee More Headlines Receive EMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emyria and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolASX:EMD CUSIPN/A CIKN/A Webwww.emeraldclinics.com.au Phone61 8 6559 2800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-380.72% Return on Assets-33.63% Debt Debt-to-Equity Ratio311.99 Current Ratio0.56 Quick Ratio2.69 Sales & Book Value Annual Sales$1.95 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow6.67 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares408,990,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.79 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Michael WinloMD & DirectorDr. Alistair VickeryExecutive Medical Director & DirectorMr. Joseph Daniel Ohayon ACAMBA Intl Bus., Chief Financial OfficerMs. Sara PolanskiCommunications & Brand ManagerMs. Tracie ErnenweinHead of Research & Drug DevelopmentMary-Ann RennieHead of Corporate OperationsMs. Susan Patricia Park A.C.A. (Age 49)A.C.I.S., ACSA, AGIA, B.Com., F Fin, FCIS, Company Secretary More ExecutivesKey Competitors1st GroupASX:1STAclarionNASDAQ:ACONWAlcidion GroupASX:ALCArcturis DataOTCMKTS:SSYNFArtryaASX:AYAView All CompetitorsInsidersAlistair VickerySold 25,488 sharesTotal: $1,758.67 ($0.07/share)Michael WinloBought 200,000 shares on 8/8/2023Total: $19,200.00 ($0.10/share) This page (ASX:EMD) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emyria Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Emyria With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.